Maze Therapeutics' Chief Medical Officer Sold 100% of His Direct Holdings. Here's What This Means for Investors.
Key Points
Chief Medical Officer Harold Bernstein sold 15,000 company shares for a transaction value of ~$442,000 at around $29.46 per share on April 1, 2026.
This disposition represented 100% of Harold Bernstein's direct Common Stock holdings, reducing his direct ownership of Common Stock to zero.
The transaction involved the exercise and immediate sale of options; Bernstein no longer holds any direct shares of Common Stock following this transaction.
- 10 stocks we like better than Maze Therapeutics ›
Maze Therapeutics (NASDAQ:MAZE) R&D President and Chief Medical Officer Harold Bernstein reported a sale of 15,000 shares of Common Stock for a total of approximately $442,000 on April 1, 2026, through an exercise of options with immediate disposition, as disclosed in a SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 15,000 |
| Transaction value | ~$442,000 |
| Post-transaction shares (direct) | 0 |
| Post-transaction value (direct ownership) | $0 |
Transaction value based on SEC Form 4 weighted average purchase price ($29.46).
Key questions
- How does this transaction affect Harold Bernstein's exposure to Maze Therapeutics?
Bernstein's direct Common Stock holdings were reduced to zero; however, his beneficial exposure continues via 237,407 directly held outstanding stock options, providing the ability to acquire Common Stock in the future. - Was this sale routine or discretionary, and what is the derivative context?
The sale involved the exercise of 15,000 options, immediately converted to shares and sold. - What portion of Bernstein's total holdings did this trade represent, and are there other classes involved?
This transaction represented 100% of Bernstein's direct Common Stock holdings. - How does the transaction size relate to Bernstein's recent trading activity?
While Bernstein's earlier administrative transactions involved a range of trade sizes, this complete disposition of direct shares reflects the culmination of a multi-step reduction strategy, consistent with declining direct holdings capacity over recent months.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 4/1/26) | $29.05 |
| Market capitalization | $1.43 billion |
| Net income (TTM) | ($131.12 million) |
| 1-year price change | 208.05% |
Note: 1-year price change calculated using April 1, 2026 as the reference date.
Company snapshot
- Maze Therapeutics develops small molecule precision medicines targeting renal, cardiovascular, metabolic diseases, and obesity; lead assets include MZE829 (APOL1 inhibitor, Phase II) and MZE782 (SLC6A19 inhibitor, Phase I).
- It operates a clinical-stage biopharmaceutical model focused on the development of proprietary therapeutics.
- The company targets patients with chronic kidney and metabolic diseases, with a focus on addressing unmet medical needs in the United States healthcare market.
Maze Therapeutics is a clinical-stage biotechnology company leveraging genetic insights to develop precision medicines for complex diseases. With a focused pipeline in renal and metabolic disorders, Maze Therapeutics aims to advance novel small molecule therapies through clinical development.
What this transaction means for investors
The complete disposition of all directly-held Maze Therapeutics shares on April 1 by Chief Medical Officer Harold Bernstein is not necessarily a red flag. He sold the stock as part of his Rule 10b5-1 trading plan, adopted in September of 2025.
A Rule 10b5-1 trading plan is frequently implemented by insiders to avoid accusations of making trades based on insider information. Moreover, he retains over 237,000 stock options.
Bernstein’s sale came at a time when Maze Therapeutics stock was experiencing a decline. Shares hit a 52-week high of $53.65 in March, thanks to encouraging clinical trial data. But with a soaring valuation, investors began cashing in, which led to the drop.
Currently, Maze Therapeutics does not produce revenue. It exited 2025 with a net loss of $131.1 million. Despite the recent fall in share price, investing in the company entails high risk. Investors should have conviction that its lead kidney drug, MZE829, can eventually achieve federal approval before deciding to buy shares.
Should you buy stock in Maze Therapeutics right now?
Before you buy stock in Maze Therapeutics, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Maze Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,087,496!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 4, 2026.
Robert Izquierdo has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
